Discouraging OS Results With Bevacizumab in Ovarian Cancer

Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer.

Source: CancerNetwork - June 26, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news